AR092530A1 - Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento - Google Patents

Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento

Info

Publication number
AR092530A1
AR092530A1 ARP130103248A ARP130103248A AR092530A1 AR 092530 A1 AR092530 A1 AR 092530A1 AR P130103248 A ARP130103248 A AR P130103248A AR P130103248 A ARP130103248 A AR P130103248A AR 092530 A1 AR092530 A1 AR 092530A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
pyrazol
dimethyl
amine
Prior art date
Application number
ARP130103248A
Other languages
English (en)
Inventor
N Casillas Linda
P Dmartino Michael
M Ramanjulu Joshi
Jr Singhaus Robert
F Mehlmann John
A Haile Pamela
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278701&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR092530A1 publication Critical patent/AR092530A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Reivindicación 1: Un compuesto de amino-quinolina caracterizado porque es de la fórmula (1), en la que: R¹ es alquilo C₁₋₆, halo-alquilo C₁₋₆, cicloalquilo C₃₋₆ o heterocicloalquilo de 4 - 6 miembros, en donde: dicho alquilo C₁₋₆ está opcionalmente sustituido con un grupo seleccionado del grupo que consiste en ciano, hidroxilo, alcoxi C₁₋₆, alcoxi C₁₋₆alcoxi C₂₋₆, -CO₂H, -CO₂-alquilo C₁₋₄, -SO₂-alquilo C₁₋₄, cicloalquilo C₃₋₆ y heterocicloalquilo de 4 - 6 miembros, en donde dicho cicloalquilo C₃₋₆ o heterocicloalquilo de 4 - 6 miembros está opcionalmente sustituido con 1 ó 2 grupos cada uno seleccionado independientemente del grupo que consiste en halógeno, -CF₃, hidroxilo, amino, alquil C₁₋₄-amino-, alquil C₁₋₄-alquil C₁₋₄-amino-, alquilo C₁₋₄, hidroxi-alquilo C₁₋₄ y alcoxi C₁₋₄, dicho cicloalquilo C₃₋₆ o heterocicloalquilo de 4 - 6 miembros está opcionalmente sustituido con 1 - 3 grupos seleccionados cada uno independientemente del grupo que consiste en halógeno, -CF₃, hidroxilo, ciano, amino, alquil C₁₋₄-amino-, alquil C₁₋₄-alquil C₁₋₄amino-, alquilo C₁₋₄, hidroxi-alquilo C₁₋₄-, oxo y alcoxi C₁₋₄ y R² es fluoro, hidroxi, alcoxi C₁₋₆-, halo-alcoxi C₁₋₆-, alcoxi C₁₋₄alcoxi C₂₋₆, halo-alcoxi C₁₋₄alcoxi C₂₋₆-, hidroxi-alcoxi C₂₋₆-, cicloalquil C₃₋₆-alcoxi C₁₋₄-, cicloalquil C₃₋₆-oxi-, heterocicloalquil (de 4 - 6 miembros)-alcoxi C₁₋₄ o heterocicloalquil (de 4 - 6 miembros)-oxi-, en donde el resto halo-alquilo C₁₋₆ del halo-alcoxi C₁₋₆- y el resto haloalquilo C₁₋₄ de los grupos halo-alcoxi C₁₋₄alcoxi C₂₋₆- contienen 1, 2 ó 3 átomos de fluoro, en donde el resto cicloalquilo C₃₋₆ del cicloalquil C₃₋₆-alcoxi C₁₋₄- o el cicloalcoxi C₃₋₆- está opcionalmente sustituido con un grupo seleccionado del grupo que consiste en ciano, halo, hidroxilo, alcoxi C₁₋₆ y alcoxi C₁₋₄alcoxi C₂₋₆, y en donde el resto heterocicloalquilo de 4 - 6 miembros del heterocicloalquil (de 4 - 6 miembros)-alcoxi C₁₋₄- o heterocicloalquil (de 4 - 6 miembros)-oxi- está opcionalmente sustituido con un grupo seleccionado del grupo que consiste en ciano, halo, hidroxilo, alcoxi C₁₋₆ y alcoxi C₁₋₄alcoxi C₂₋₆; R³ es H, metilo; R⁴ es H, metilo o trifluorometilo; y R⁵ es H o alquilo C₁₋₃; o una de sus sales; con la condición de que el compuesto no sea: 6-(terc-butilsulfonil)-N-(4,5-dimetil-1H-pirazol-3-il)-7-metoxiquinolin-4-amina, 2-((4-((4,5-dimetil-1H-pirazol-3-il)amino)-7-metoxiquinolin-6-il)sulfonil)-2-metilpropan-1-ol, N-(4,5-dimetil-1H-pirazol-3-il)-7-metoxi-6-((tetrahidro-2H-piran-4-il)sulfonil)quinolin-4-amina, N-(4,5-dimetil-1H-pirazol-3-il)-6-((2,2-dimetiltetrahidro-2H-piran-4-il)sulfonil)-7-metoxiquinolin-4-amina, N-(4,5-dimetil-1H-pirazol-3-il)-7-metoxi-6-((4-metiltetrahidro-2H-piran-4-il)sulfonil)quinolin-4-amina, N-(4,5-dimetil-1H-pirazol-3-il)-7-metoxi-6-((2-metoxietil)sulfonil)quinolin-4-amina, N-(4,5-dimetil-1H-pirazol-3-il)-7-metoxi-6-(((3R,4R)-3-metiltetrahidro-2H-piran-4-il)sulfonil)quinolin-4-amina, N-(4,5-dimetil-1H-pirazol-3-il)-6-(((2R,6S)-2,6-dimetiltetrahidro-2H-piran-4-il)sulfonil)-7-metoxiquinolin-4-amina, 6-(terc-butilsulfonil)-4-((4,5-dimetil-1H-pirazol-3-il)amino)quinolin-7-ol, 2-{[4-[(4,5-dimetil-1H-pirazol-3-il)amino]-7-(metiloxi)-6-quinolinil]sulfonil}etanol, N-(4,5-dimetil-1H-pirazol-3-il)-6-[(1-metiletil)sulfonil]-7-(metiloxi)-4-quinolinamina, 6-(isopropil-sulfonil)-7-metoxi-N-(4-metil-5-(trifluorometil)-1H-pirazol-3-il)quinolin-4-amina, 6-(terc-butilsulfonil)-7-metoxi-N-(4-metil-5-(trifluorometil)-1H-pirazol-3-il)quinolin-4-amina, 6-(terc-butilsulfonil)-N-(4,5-dimetil-1H-pirazol-3-il)-7-etoxiquinolin-4-amina, 7-metoxi-N-(4-metil-5-(trifluorometil)-1H-pirazol-3-il)-6-((tetrahidro-2H-piran-4-il)sulfonil)quinolin-4-amina, 2-((6-(terc-butilsulfonil)-4-((4,5-dimetil-1H-pirazol-3-il)amino)quinolin-7-il)oxi)etanol, 6-(terc-butilsulfonil)-7-(difluorometoxi)-N-(4,5-dimetil-1H-pirazol-3-il)quinolin-4-amina, o 7-(difluorometoxi)-N-(4,5-dimetil-1H-pirazol-3-il)-6-((tetrahidro-2H-piran-4-il)sulfonil)quinolin-4-amina, o una de sus sales.
ARP130103248A 2012-09-13 2013-09-11 Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento AR092530A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700536P 2012-09-13 2012-09-13
US201361767378P 2013-02-21 2013-02-21

Publications (1)

Publication Number Publication Date
AR092530A1 true AR092530A1 (es) 2015-04-22

Family

ID=50278701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103248A AR092530A1 (es) 2012-09-13 2013-09-11 Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento

Country Status (21)

Country Link
US (1) US9216965B2 (es)
EP (1) EP2895167B1 (es)
JP (1) JP6258331B2 (es)
KR (1) KR20150053920A (es)
CN (1) CN104602692B (es)
AR (1) AR092530A1 (es)
AU (1) AU2013315387B2 (es)
BR (1) BR112015004967A2 (es)
CA (1) CA2883155A1 (es)
CL (1) CL2015000615A1 (es)
CR (1) CR20150133A (es)
DO (1) DOP2015000059A (es)
EA (1) EA027984B1 (es)
ES (1) ES2713172T3 (es)
IL (1) IL237158A0 (es)
MX (1) MX2015003275A (es)
PE (1) PE20150774A1 (es)
PH (1) PH12015500345A1 (es)
SG (1) SG11201500973WA (es)
TW (1) TW201425307A (es)
WO (1) WO2014043437A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN107158385B (zh) * 2016-03-14 2020-07-14 苏州大学 Rip3抑制剂在制备抗血小板血栓药物中的用途
EP3445759A1 (en) 2016-04-20 2019-02-27 GlaxoSmithKline Intellectual Property Development Ltd Conjugates comprising ripk2 inhibitors
WO2020094613A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Nod2 inhibitors for the treatment of hereditary periodic fevers

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU3969697A (en) 1996-08-01 1998-02-25 Dow Agrosciences Llc Quinolinium derivatives having fungicidal activity
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6593333B1 (en) 1998-10-01 2003-07-15 Astrazeneca Ab Substituted anilino-quinazoline (or quinoline) compounds and use thereof
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP4870304B2 (ja) 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
AU2001228638A1 (en) 2000-01-28 2001-08-07 Astrazeneca Ab Chemical compounds
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
BR0113056A (pt) 2000-08-09 2003-07-08 Astrazeneca Ab Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
CN100491372C (zh) 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20040122161A1 (en) 2002-12-21 2004-06-24 Paul Charles W. Hot melt adhesive based on acrylic block copolymers
WO2004058781A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
BRPI0410720A (pt) 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
UA84167C2 (ru) 2003-09-16 2008-09-25 Астразенека Аб Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
PL2210607T3 (pl) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka
NZ547009A (en) 2003-12-23 2009-09-25 Pfizer Novel quinoline derivatives
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
WO2005115145A2 (en) 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
JP2008500374A (ja) 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド 自己炎症性疾患の処置のためのｉｃｅインヒビター
EP1781293A1 (en) 2004-06-04 2007-05-09 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
FR2873695A1 (fr) 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
EP1833830B1 (de) 2004-12-22 2009-10-14 Bayer Schering Pharma Aktiengesellschaft Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
ITMI20052008A1 (it) 2005-10-21 2007-04-22 Ctg Pharma S R L Nuovi antimalarici derivati della 4-aminochinolina
FR2902100A1 (fr) 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
US7511063B2 (en) 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
AU2007296744A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
WO2008119771A2 (en) 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2152267A2 (en) 2007-06-01 2010-02-17 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
CN101362719B (zh) 2007-08-06 2012-04-18 北京师范大学 喹啉类衍生物以及包含其的组合物
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
US20130005726A1 (en) 2010-03-08 2013-01-03 Derek Abbott Compositions and methods for treating inflammatory disorders
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
US20130023534A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Pyrazolyl-pyrimidines as kinase inhibitors
WO2011123609A1 (en) 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
EP2566477B1 (en) 2010-05-07 2015-09-02 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9133162B2 (en) * 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
JP6026441B2 (ja) * 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы

Also Published As

Publication number Publication date
EA201590552A1 (ru) 2015-06-30
EP2895167A4 (en) 2016-03-16
CL2015000615A1 (es) 2015-08-28
JP6258331B2 (ja) 2018-01-10
IL237158A0 (en) 2015-04-30
TW201425307A (zh) 2014-07-01
AU2013315387B2 (en) 2016-09-08
PE20150774A1 (es) 2015-05-28
DOP2015000059A (es) 2015-05-15
JP2015528508A (ja) 2015-09-28
KR20150053920A (ko) 2015-05-19
EP2895167A1 (en) 2015-07-22
EA027984B1 (ru) 2017-09-29
CN104602692B (zh) 2017-06-23
CA2883155A1 (en) 2014-03-20
AU2013315387A1 (en) 2015-02-26
US9216965B2 (en) 2015-12-22
MX2015003275A (es) 2015-07-06
SG11201500973WA (en) 2015-04-29
BR112015004967A2 (pt) 2020-04-22
WO2014043437A1 (en) 2014-03-20
EP2895167B1 (en) 2018-12-05
CR20150133A (es) 2015-05-04
ES2713172T3 (es) 2019-05-20
CN104602692A (zh) 2015-05-06
US20150094333A1 (en) 2015-04-02
PH12015500345A1 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
AR092530A1 (es) Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR082620A1 (es) Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR079231A1 (es) Derivados de imidazoquinolina
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MY170729A (en) 4-(8-methoxy -i- (( 1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
AR117102A1 (es) Inhibidores de arg1 y/o arg2
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR087355A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
AR076692A1 (es) Piperidinas sustituidas
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
AR055344A1 (es) Derivados de 1-oxoindano y 1-oxo-2,3-dihidroisoindol como inhibidores de p38, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la cinasa p38

Legal Events

Date Code Title Description
FB Suspension of granting procedure